Evidence method
Level · gp.fundamentals.capex_revenue_ratio
16.02% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ALNY · Jun 30, 2020
ALNYLAM PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001178670-20-000015General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-130.17% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Yoy · gp.fundamentals.revenue
132.50% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
74.47% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.gross_margin
80.83% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-191.28% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
149.09% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
32.47% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History17 statesSelf-history eligible
Sep 30, 20180/7 normalizedLevel 3Dec 31, 20180/7 normalizedLevel 3Mar 31, 20190/7 normalizedLevel 3Jun 30, 20190/8 normalizedLevel 3Sep 30, 20190/8 normalizedLevel 3Dec 31, 20190/8 normalizedLevel 3Mar 31, 20200/8 normalizedLevel 3Jun 30, 20204/8 normalizedLevel 3Sep 30, 20207/8 normalizedLevel 3Dec 31, 20207/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Sep 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 19.72%
- Current
- 16.02%
- Delta
- -3.70%
- Previous
- -247.46%
- Current
- -130.17%
- Delta
- 117.29%
- Previous
- 198.78%
- Current
- 132.50%
- Delta
- -66.28%
- Previous
- 68.66%
- Current
- 74.47%
- Delta
- 5.81%
- Previous
- 86.63%
- Current
- 80.83%
- Delta
- -5.80%
- Previous
- -211.26%
- Current
- -191.28%
- Delta
- 19.98%
- Previous
- 170.46%
- Current
- 149.09%
- Delta
- -21.38%
- Previous
- 34.76%
- Current
- 32.47%
- Delta
- -2.29%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ALNY Fundamental State →Has State · ALNYLAM PHARMACEUTICALS, INC. →Transitioned To · ALNY Fundamental State →Transitioned To · ALNY CAPEX_INTENSITY_DECREASED →Transitioned To · ALNY CASH_GENERATION_INCREASED →Transitioned To · ALNY GROWTH_DECREASED →Transitioned To · ALNY INVENTORY_PRESSURE_INCREASED →Transitioned To · ALNY MARGIN_DECREASED →Transitioned To · ALNY PROFITABILITY_INCREASED →Transitioned To · ALNY R_AND_D_INTENSITY_DECREASED →Transitioned To · ALNY SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.